智通财经APP获悉，辉瑞(PFE.US)同意以约49亿美元的企业价值收购肥胖症药物研发初创公司 Metsera(MTSR.US)，此举旨在强化其研发管线。此前，该公司一款关键减肥药研发受挫。 这家美国制药商在周一的声明中表示，将以每股47.50美元的现金收购Metsera，若达成三项特定监管里 程碑，还将额外支付每股最高22.50美元。该交易较Metsera上周五收盘价溢价43%。截至发稿，Metsera 盘前涨59.72%，报53.22美元。 新冠疫情过后，辉瑞正致力于业务重整，将希望寄托于尚未经过验证的新药研发管线，以接替其老化产 品。作为新一代肥胖症药物研发中有望脱颖而出的企业之一，Metsera正在开发多款实验性减肥药物， 其中包括一款注射剂，其给药频率可能低于市场主流产品Wegovy和Zepbound。 该公司研发的药物MET-233i在最近一项研究中，帮助患者在36天内减重高达8.4%。该药物仍处于早期 开发阶段，这意味着距离上市还有数年时间。 彭博行业研究的迈克尔·沙阿表示，MET-233i"可能成为肥胖症治疗领域最具潜力的同类最佳药物"。 ...

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera. The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 per share in cash for each Metsera share. That represents a premium of more than 42% to Metsera’s closing price Friday. Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline develops. Metsera has no products on the market, but its pipeline includes four programs in ...

公司收购与战略布局 - 辉瑞宣布收购临床阶段生物制药公司 交易金额最高达70亿美元 [1] - 收购目标为进入目前由礼来和诺和诺德主导的减肥药市场 [1] 行业竞争格局 - 减肥药市场目前被礼来和诺和诺德两家公司主导 [1] - 辉瑞通过收购临床阶段公司寻求进入该 lucrative 市场 [1]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Pfizer is back in the obesity drug chase, announcing Monday it will pay $4.9 billion, and potentially more, to buy Metsera and its portfolio of weight loss medicines. Per deal terms, Pfizer will pay $47.50 for each Metsera share, more than double the $18 price the company debuted at following an initial public offering in January. Metsera shareho ...

辉瑞正以高达73亿美元的总价收购减肥药开发商Metsera。此交易包括每股47.50美元的现金以及或有支付，相较于Metsera上周五的收盘价溢价约 42.5%。美股盘前Metsera股价大涨51.26%，市值达到约35亿美元。 在自身减肥药研发遭遇挫折后，辉瑞正通过一笔重大收购重新布局，以期在这个规模有望突破千亿美元的赛道中占据一席之地。 据媒体22日报道， 辉瑞已接近达成一项交易，计划以高达73亿美元的总价收购减肥药开发商Metsera。 报道称，辉瑞将以每股47.50美元的现金收购这 家总部位于纽约的公司，并根据特定业绩里程碑的达成情况，额外支付最高每股22.50美元。 这一收购价较Metsera周五33.32美元的收盘价溢价约42.5%。美股盘前Metsera股价大涨51.26%，市值达到约35亿美元。 根据交易条款，辉瑞提出的每股47.50美元现金报价，相较于Metsera上周五的收盘价存在显著溢价。按该收盘价计算，Metsera的市值约为35亿美元 （据LSEG数据）。包含或有价值支付在内， 这笔交易的总金额最高可达73亿美元。 辉瑞此前在减肥药自主开发方面遭遇重大挫折。 该公司曾研发实验性减肥药 ...

Pfizer (PFE), a pharmaceutical and biotechnology company, rose to great heights during the pandemic with its COVID-19 vaccine. However, it has spent the last few years attempting to reposition itself following the post-pandemic decline in COVID-related revenues. Many investors have written off the stock due to deteriorating sales of Comirnaty and Paxlovid, as well as concerns that its recovery strategies will fail to produce long-term growth. Pfizer stock has dipped 19.3% over the past 52 weeks and 9.7% ye ...

每经AI快讯，9月22日，辉瑞盘前继续走高涨2.7%。 ...

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs. ...

Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market. ...

"Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,†said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "We are excited to apply our deep cardiometabolic experience and manufacturing and commercial infrastructure to accelerate a portfolio that includes potential best-in-class injectabl ...